Abstract
The ReCor Medical Paradise® Renal Denervation System delivers ultrasound energy to perform targeted circumferential denervation to the renal afferent and efferent sympathetic nerves with the goal of achieving a reduction in systemic arterial blood pressure, and mitigating end organ effects due to sympathetic over-activity. Ultrasound energy is a controllable energy source which does not require direct tissue contact to heat the tissue providing a unique therapeutic advantage in the application of renal denervation. The Paradise System has been designed to deliver energy to create an optimized tissue thermal profile to achieve targeted ablation of nerves surrounding the renal artery, while preserving the integrity of the renal arterial wall through a unique cooling mechanism. The tissue thermal profile has been optimized through pre-clinical in vitro and in vivo testing. Feasibility clinical studies have demonstrated the safety and effectiveness in controlling resistant hypertension of the system out to 12 months. On-going and future clinical studies will allow for a continued assessment of the overall safety, effectiveness, and durability of the Paradise System.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Fisher, et al. Central sympathetic overactivity: maladies and mechanisms. Auton Neurosci. 2009;148:5–15.
Esler M. The 2009 Carl Ludwig lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol. 2010;108:227–37.
DiBona G, Kopp U. Neural control of renal function. Physiol Rev. 1997;77:75–197.
Mancia G, et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension. 1999;34:724–8.
Calhoun D, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure. Circulation. 2008;117:e510–26.
Mancia G, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34:2159–219.
Schlaich M, et al. Renal denervation and hypertension. Am J Hypertens. 2011;24:635–42.
Schlaich M, et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. JACC. 2013. doi:10.1016/j.jacc.2013.08.1616.
Krum H, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.
Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.
Esler M, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): a randomized controlled trial. Lancet. 2010;376:1903–9.
Esler M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the symplicity HTN-2 randomized controlled trial. Circulation. 2012;126:2976–82.
Mabin T, et al. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2012;8:57–61.
Kennedy, et al. High intensity focused ultrasound: surgery of the future? Br J Radiol. 2003;76:590–9.
Mancia G, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462–536.
Mahfound, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013. doi:10.1161/CIRCULATIONAHA.112.000949.
Montelescot G, et al. REALISE trial: Renal Denervation by Ultrasound Transcatheter Emission. TCT 2014.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Sapoval, M., Pathak, A., Coleman, L.A., Roth, A.R., Reeve, H.L., Zeller, T. (2015). ReCor Medical Paradise® Renal Denervation System. In: Heuser, R., Schlaich, M., Sievert, H. (eds) Renal Denervation. Springer, London. https://doi.org/10.1007/978-1-4471-5223-1_9
Download citation
DOI: https://doi.org/10.1007/978-1-4471-5223-1_9
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-5222-4
Online ISBN: 978-1-4471-5223-1
eBook Packages: MedicineMedicine (R0)